You lost 20 pounds on semaglutide. Your doctor is thrilled. Your A1C dropped. Your blood pressure improved. Everything on paper looks perfect.

But you’re weaker. Your grip feels different. You get winded on stairs you used to take without thinking. Your knees ache in ways they didn’t six months ago. And when you stand on the body composition scale at the gym, something alarming is hiding under the “weight lost” headline: you didn’t just lose fat. You lost a significant amount of muscle. And your bone density may be going with it.

This isn’t a fringe concern. It’s published data. And it matters more for women over 35 than anyone else.

What’s actually happening

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda) — work by mimicking a gut hormone that tells your brain you’re full. They suppress appetite dramatically, which creates a large calorie deficit, which produces rapid weight loss.

The weight loss is real. But the composition of that weight loss is the problem nobody talks about.

A network meta-analysis published in PubMed found that potent GLP-1 RAs like tirzepatide and semaglutide “demonstrate greater overall weight loss but are associated with a significant reduction in lean mass” (Lundsgaard et al., 2024 — PubMed). Specifically:

  • Semaglutide: up to 40% of weight lost was lean mass (muscle, bone, connective tissue), not fat.
  • Liraglutide: up to 60% lean mass loss in some studies.
  • A case series in PMC confirmed that “lean soft tissue loss comprised 26%–40% of total weight loss in recent GLP-1 trials” (PMC12536186).

Let that number sink in. If you lost 20 pounds, 5 to 8 of those pounds may have been muscle — the exact tissue that keeps your metabolism running, your bones protected, and your body functional.

The bone density connection

It’s not just muscle. GLP-1 drugs are now linked to bone loss and increased fracture risk.

A large study published in March 2026 found that about 4% of GLP-1 users developed osteoporosis compared to 3% of non-users — a 30% increased risk. A related condition, osteomalacia (softening of bone), occurred at approximately twice the rate in GLP-1 users (NBC News, March 2026 — link).

The SELECT cardiovascular outcomes trial revealed an even more specific signal: hip and pelvic fractures occurred at 1.0% in female semaglutide patients versus 0.2% in placebo — a five-fold increase (PMC12628458 — link). The FDA’s own label for semaglutide warns that it “might increase the risk of bone fractures in older adults and women.”

For women over 35 — who are already losing bone density from estrogen decline — this is not a minor risk. It’s stacking two bone-loss mechanisms on top of each other.

Why this matters more for women

The reason this hits women harder than men:

1. Women start with less muscle mass. Men have approximately 36% more lean mass than women on average. When both sexes lose 30% of weight as muscle, the absolute loss is more functionally significant for women — because they had less buffer to begin with.

2. Women are already losing bone density. After 35, estrogen decline accelerates bone loss at approximately 1-2% per year. Adding GLP-1-induced bone loss on top of menopausal bone loss is a compounding problem.

3. Women live longer. The muscle and bone you lose at 45 determines your mobility at 75. Rapid muscle loss now means frailty later. This isn’t a scare tactic — it’s longitudinal data.

4. Women’s insulin resistance is different. Women’s insulin resistance is more connected to estrogen decline than to lifestyle alone. Treating the insulin with a GLP-1 without addressing the hormonal driver means you’re suppressing the symptom while the root cause continues. When you stop the drug, the weight returns — but the muscle doesn’t.

A review in Circulation (AHA Journals) put it directly: “Semaglutide has been associated with loss of lean mass up to 40% of total weight loss” (AHA Journals). The SEMALEAN study is currently evaluating semaglutide’s specific impact on lean mass, muscle function, and metabolic adaptations — results that should be available later this year (PMC12673431).

What to do if you’re on a GLP-1

This is not a “stop your medication” post. GLP-1 drugs have real benefits for people with type 2 diabetes and significant obesity. But if you’re taking one — or considering one — here’s how to protect yourself:

1. Resistance training is non-negotiable

This is the single most important thing you can do. Resistance training preserves muscle during weight loss. A systematic review confirmed that weight-bearing exercise and resistance training lowered bone loss risk during GLP-1 use (GoodRx, 2026).

  • 3-4 sessions per week
  • Progressive overload
  • Compound movements (squats, deadlifts, presses)
  • This isn’t optional — it’s the protection layer

2. Protein: 0.8–1.0g per pound of goal bodyweight

When you’re in a large calorie deficit (which GLP-1s create), your body breaks down muscle for energy. Protein is the signal to preserve muscle. Most GLP-1 users are eating dramatically less protein than they need because the drug suppresses appetite. You have to intentionally prioritize it.

  • Target: 100-130g per day minimum
  • Front-load at breakfast and lunch
  • Protein shakes if you can’t eat enough solid food

3. Test your bone density

Ask your doctor for a DEXA scan before or early in GLP-1 treatment. This gives you a baseline. If you’re over 40, you should be getting one anyway. If you’re on a GLP-1, it’s essential.

4. Supplement to protect bone and muscle

  • Creatine monohydrate (3-5g/day): The most evidence-backed supplement for preserving lean mass during weight loss. Multiple meta-analyses confirm it enhances muscle strength gains when combined with resistance training.
  • Calcium + Vitamin D3: If your vitamin D is below 40 ng/mL, your bones are vulnerable. Test it. Supplement if deficient.
  • Magnesium glycinate (300-400mg): Supports both bone density and insulin signaling.

5. Don’t stop resistance training when you stop the drug

When people stop GLP-1s, the appetite returns and weight rebounds. But muscle doesn’t rebound at the same rate. If you lost 8 pounds of muscle on semaglutide, that takes 4-6 months of dedicated resistance training to rebuild. The people who maintain their results after GLP-1s are the ones who built the training habit while on them.

The honest bottom line

GLP-1 drugs work for weight loss. Nobody disputes that. But “working” and “being healthy” are not the same thing. A drug that removes 40% lean mass and increases fracture risk is doing something your body won’t thank you for in 10 years.

If you’re going to use one, use it with your eyes open: train hard, eat protein, protect your bones, and build the habits that will sustain you when the drug stops.

The weight loss is temporary. The muscle and bone loss doesn’t have to be permanent. But only if you actively protect them.

This post contains affiliate links. If you purchase through these links, we may earn a small commission at no extra cost to you. We only recommend products we’ve researched and believe in.

Sources

  • Lundsgaard AM, et al. “Effect of GLP-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.” 2024. PubMed
  • PMC12536186. “Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series.” Link
  • PMC12628458. “Effects of GLP-1 receptor agonists on bone health in people living with obesity.” Link
  • NBC News. “GLP-1s may increase risk of osteoporosis and gout, new research finds.” March 2026. Link
  • Circulation (AHA). “Muscle Mass and GLP-1 Receptor Agonists.” Link
  • PMC12673431. “Impact of Semaglutide on fat mass, lean mass and muscle function: The SEMALEAN study.” Link